IRIS
DUMINUCO, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.052
EU - Europa 1.694
AS - Asia 1.601
AF - Africa 246
SA - Sud America 184
Continente sconosciuto - Info sul continente non disponibili 68
OC - Oceania 5
Totale 5.850
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.978
IT - Italia 716
SG - Singapore 705
RU - Federazione Russa 627
CN - Cina 484
BR - Brasile 147
CI - Costa d'Avorio 147
KR - Corea 134
VN - Vietnam 98
IE - Irlanda 54
BD - Bangladesh 52
FR - Francia 52
SE - Svezia 50
GB - Regno Unito 40
CA - Canada 37
FI - Finlandia 35
IN - India 35
NG - Nigeria 27
HK - Hong Kong 23
DE - Germania 22
BJ - Benin 21
SN - Senegal 21
MX - Messico 20
PL - Polonia 17
NL - Olanda 16
AR - Argentina 15
UA - Ucraina 14
IQ - Iraq 13
ZA - Sudafrica 13
ES - Italia 11
JP - Giappone 11
TR - Turchia 10
BE - Belgio 9
CZ - Repubblica Ceca 7
VE - Venezuela 6
AU - Australia 5
CO - Colombia 5
EG - Egitto 5
PK - Pakistan 5
BO - Bolivia 4
GT - Guatemala 4
JM - Giamaica 4
JO - Giordania 4
KE - Kenya 4
LT - Lituania 4
PH - Filippine 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
DZ - Algeria 3
EC - Ecuador 3
HR - Croazia 3
LB - Libano 3
RO - Romania 3
AZ - Azerbaigian 2
CR - Costa Rica 2
CY - Cipro 2
ID - Indonesia 2
KZ - Kazakistan 2
OM - Oman 2
PT - Portogallo 2
PY - Paraguay 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
BF - Burkina Faso 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
CH - Svizzera 1
CL - Cile 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
HN - Honduras 1
HU - Ungheria 1
IR - Iran 1
KW - Kuwait 1
KY - Cayman, isole 1
LV - Lettonia 1
MA - Marocco 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RS - Serbia 1
SA - Arabia Saudita 1
SC - Seychelles 1
SO - Somalia 1
SV - El Salvador 1
TJ - Tagikistan 1
UZ - Uzbekistan 1
Totale 5.782
Salva come PNG Salva come JPEG
Città #
Singapore 481
Dallas 349
Moscow 330
Santa Clara 248
Hefei 237
San Jose 193
Ashburn 163
Abidjan 147
Seoul 133
Chicago 122
Catania 119
Los Angeles 90
Council Bluffs 74
Beijing 61
Dublin 52
New York 51
Palermo 50
Civitanova Marche 48
Milan 45
Chandler 43
Rome 42
Boardman 38
Lauterbourg 38
Buffalo 34
Ho Chi Minh City 34
Cotonou 21
Dakar 21
Orem 20
Hong Kong 19
São Paulo 19
Hanoi 18
Lagos 18
Lappeenranta 18
Warsaw 17
Montreal 16
Bari 13
Chennai 13
Florence 13
Phoenix 13
Boston 12
Helsinki 12
Johannesburg 12
San Giovanni la Punta 12
Stockholm 12
Acireale 11
Amsterdam 11
Naples 11
Tokyo 11
Denver 10
Turin 10
Abuja 9
Brussels 9
London 9
Misterbianco 9
Paris 9
Rio de Janeiro 9
San Francisco 9
Washington 9
Bronte 8
Messina 8
Munich 8
Seattle 8
Atlanta 7
Lawrence 7
Manchester 7
Mexico City 7
Poplar 7
Pozzallo 7
Belo Horizonte 6
Brooklyn 6
Cambridge 6
Frankfurt am Main 6
Mumbai 6
Cassano delle Murge 5
Charlotte 5
City of London 5
Houston 5
Louisville 5
Piazzola Sul Brenta 5
Turku 5
Ankara 4
Baghdad 4
Bergamo 4
Brno 4
Genoa 4
Haiphong 4
Kingston 4
Kyiv 4
Melbourne 4
Piscataway 4
Pittsburgh 4
Aci Sant'Antonio 3
Amman 3
Bogotá 3
Brasília 3
Bắc Ninh 3
Cairo 3
Caltagirone 3
Campinas 3
Can Tho 3
Totale 3.867
Salva come PNG Salva come JPEG
Nome #
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 220
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis 193
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 172
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 169
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 167
Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients 165
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 164
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 162
A case of high-risk AML in a patient with advanced systemic mastocytosis 162
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 156
Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience 147
Renal extramedullary hematopoiesis as an epiphenomenon of bone marrow dysfunction in a patient with primary myelofibrosis: A rare case report 140
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 137
Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study 132
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 131
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology 130
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions 130
Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers 129
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients 127
Emerging Therapeutic Approaches for Anemia in Myelofibrosis 127
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting 127
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field 126
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data 123
Emergencies in Hematology: Why, When and How I Treat? 122
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes 122
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib 121
Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study 119
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future 114
Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters 114
Chemotherapy extravasation: diagnosis, prevention and management 113
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases 112
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes 111
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease 110
VEXAS-like syndrome: a potential new entity? 102
Multicentric Castleman disease and concurrent hematological disorders: the occurrence of plasmacytoma and the hypotheses arising from literature's review 101
Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association 99
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study 96
Transient Leukemoid Reaction from T-Cell Large Granular Lymphocytes Post Autologous Stem Cell Transplant in a Patient Affected by Hodgkin Lymphoma 94
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 91
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey 85
Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms 80
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point? 79
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib 78
The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors 70
Myelofibrosis: In Search for BETter Targeted Therapies 60
Exploring the ABO haplotype and splanchnic thrombosis in patients with Primary Myelofibrosis 29
Pericytes and mesenchymal stromal cells converge toward pro-tumor phenotypes in the tumor microenvironment 25
Glutamate accumulation in myelofibrosis microenvironment rewires mesenchymal stromal cells metabolic and epigenetic profiles 17
Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model 16
Prothrombotic profiles in myelofibrosis: Fibrinogen oxidation and the beneficial effects of ruxolitinib 15
A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications 13
Heme oxygenase-1/CO signaling suppresses NLRP3 inflammasome–mediated stromal fibrosis in primary myelofibrosis 13
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study 12
Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with Venetoclax 11
Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database 9
BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders 8
Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real‐world evidence 8
Debulking Therapy with Obinutuzumab Is Helpful and Safe in Chronic Lymphocytic Leukemia with Extreme Hyperleukocytosis: A Case Report 8
Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic Landscape 8
Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience 8
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study 6
Hepcidin as a Molecular Hub of Iron Homeostasis: From BMP–SMAD Signaling to Therapeutic Modulation 6
Survival and quality‐of‐life implications of cytopenia trajectories in ruxolitinib‐treated myelofibrosis 6
Real-World Outcomes in FLT3-ITD Mutated Acute Myeloid Leukemia: Impact of NPM1 Mutations and Allogeneic Transplantation in a Retrospective Unicentric Cohort 3
Totale 5.850
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.911
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.911
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202252 0 0 0 0 6 4 3 1 6 14 5 13
2022/2023230 7 15 5 12 12 20 7 43 51 14 34 10
2023/2024474 26 60 22 55 13 88 33 36 6 17 80 38
2024/20251.189 16 174 41 114 190 121 60 45 71 85 123 149
2025/20263.521 226 425 411 224 425 765 263 83 233 228 156 82
2026/2027384 73 224 87 0 0 0 0 0 0 0 0 0
Totale 5.850